NCT03553823 - Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 14, 2019

Primary Completion Date

January 28, 2020

Study Completion Date

January 28, 2020

Conditions

Chronic Plaque-type Psoriasis

Interventions

PROCEDURE

Skin biopsies

At Baseline, two 6-mm punch biopsies were taken, one from the identified active plaque (TCS ≥ 6) and one from never-lesional skin. At the End-of-study Visit, one biopsy was taken from the same area of the active plaque sampled at Baseline.

Trial Locations (14)

13353

Novartis Investigative Site, Berlin

19140

Novartis Investigative Site, Philadelphia

22391

Novartis Investigative Site, Hamburg

24105

Novartis Investigative Site, Kiel

44791

Novartis Investigative Site, Bochum

53105

Novartis Investigative Site, Bonn

56242

Novartis Investigative Site, Selters

60590

Novartis Investigative Site, Frankfurt

70112

Novartis Investigative Site, New Orleans

75230

Novartis Investigative Site, Dallas

87700

Novartis Investigative Site, Memmingen

08520

Novartis Investigative Site, East Windsor

H4G 3E7

Novartis Investigative Site, Verdun

06108

Novartis Investigative Site, Halle